Lion Street Advisors LLC Has $254,000 Position in Novo Nordisk A/S (NYSE:NVO)

Lion Street Advisors LLC cut its holdings in Novo Nordisk A/S (NYSE:NVO) by 10.2% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 2,130 shares of the company’s stock after selling 241 shares during the quarter. Lion Street Advisors LLC’s holdings in Novo Nordisk A/S were worth $254,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. First PREMIER Bank acquired a new stake in Novo Nordisk A/S in the 1st quarter valued at about $25,000. 1620 Investment Advisors Inc. acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S in the 2nd quarter worth approximately $25,000. Dixon Mitchell Investment Counsel Inc. acquired a new position in Novo Nordisk A/S during the 1st quarter worth $26,000. Finally, Orion Capital Management LLC bought a new position in Novo Nordisk A/S in the 1st quarter valued at $26,000. 11.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NVO. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and an average price target of $145.17.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $120.04 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $538.68 billion, a P/E ratio of 41.11, a PEG ratio of 1.53 and a beta of 0.42. The business has a 50-day moving average of $129.39 and a 200-day moving average of $132.02. Novo Nordisk A/S has a 1 year low of $92.94 and a 1 year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). The firm had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.01 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were issued a dividend of $0.5126 per share. The ex-dividend date was Friday, August 16th. This represents a yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio is presently 24.66%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.